Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
Kenichi InoueNorikazu MasudaHiroji IwataMasato TakahashiYoshinori ItoYasuo MiyoshiTakahiro NakayamaHirofumi MukaiJan-Stefan van der WaltJoji MoriSachi SakaguchiTsutomu KawaguchiYoshinori TanizawaAntonio Llombart-CussacGeorge W SledgeMasakazu ToiPublished in: Breast cancer (Tokyo, Japan) (2021)
NCT02107703; U.S. National Library of Medicine: https://clinicaltrials.gov/ct2/show/NCT02107703 .
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- computed tomography
- quality improvement
- induced pluripotent stem cells
- image quality
- dual energy
- contrast enhanced
- randomized controlled trial
- magnetic resonance imaging
- stem cells
- clinical trial
- magnetic resonance
- study protocol
- combination therapy
- childhood cancer